NL-OMON39541已完成不适用
The clinical relevance of axillary reverse mapping (ARM) - Clinical relevance of ARM
Amphia Ziekenhuis0 个研究点目标入组 280 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 280
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Female mental competent patients of at least 18 years of age with the diagnosis invasive breast cancer with an indication for a complementary axillary lymph node dissection (ALND) based on a positive sentinel lymph node (SLN) are eligible for an ALND-ARM procedure. The indication for a complementary ALND will be made in a multidisciplinary team including an oncologic surgeon, medical oncologist, pathologist, radiologist and a radiotherapist.
排除标准
- •Exclusion criteria are: primary ALND based on a clinical positive axilla (proven by cytological punction), a contra-indication for sentinel lymph node biopsy (SLNB), a history of breast-cancer, adverse event during the previous SLNB, pregnancy.
- •Patients excluded for randomization between ALND and ALND-ARM will be possible candidates for the side study in which the feasibility of ARM (without sparing lymphatics and lymph nodes) is investigated.
研究者
相似试验
尚未招募
不适用
The clinical relevance of an armpit dissection with sparing of the nodes of the upper extrimity.Breast cancer, Axillary lymph node dissection, Breast cancer related lymphedema, Axillary reverse mappingNL-OMON28839none280
已完成
1 期
Axillary Reverse Mapping for Invasive Carcinoma of the BreastBreast CancerNCT00645541M.D. Anderson Cancer Center35
撤回
不适用
Reverse Axillary Mapping in Breast Radiation Treatment PlanningLymphedemaBreast CancerNCT04292860UNC Lineberger Comprehensive Cancer Center
已完成
不适用
Axillary Reverse Mapping in Breast CancerLymph Node Cancer MetastaticNCT05040685Hospital Universitari de Bellvitge43
进行中（未招募）
3 期
Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node DissectionBreast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage IIINCT03927027Alliance for Clinical Trials in Oncology534